![](https://www.taivex.com/wp-content/uploads/2016/09/iStock-1148337618.jpg)
First in the worldwide! Oral powder T-1101 approved by the US FDA to start Phase I clinical study
Taivex Therapeutics Corp. has identified a novel targeting small molecule anti-cancer drug, T-1101, which is oral powder for constitution (OPC). T-1101 Investigational New Drug Application